Evidence map›Paper›PMID 33923801›Full record

ArticlePharmaceuticals (Basel, Switzerland)2021

In Vitro Activity of a Novel Siderophore-Cephalosporin LCB10-0200 (GT-1), and LCB10-0200/Avibactam, against Carbapenem-Resistant

Le Phuong Nguyen, Chul Soon Park, Naina Adren Pinto, Hyunsook Lee, Hyun Soo Seo, Thao Nguyen Vu, Hung Mai, An H T Pham, Eris Jang, Young Lag Cho and 6 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Pharmaceuticals (Basel, Switzerland), 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed, 1 pooled it
0.6field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 1 synthesis or guideline pooled it, 10 citations in OpenAlex.

  1. Pooled it
  2. Siderophore cephalosporins.EcoSal Plus · 2025
    Review
  3. Difficult-to-treat (DTR)Antimicrobial agents and chemotherapy · 2024
    Article
  4. Article
  5. Review
  6. Review
  7. Antibacterial Activity of LCB10-0200 againstAntibiotics (Basel, Switzerland) · 2021
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

16 authors at 4 institutions in 2 countries.

Le Phuong NguyenDepartment of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul 03722, Korea.ORCID 0000-0001-6123-5426
Chul Soon ParkDepartment of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul 03722, Korea.
Naina Adren PintoDepartment of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul 03722, Korea.ORCID 0000-0002-8348-8990
Hyunsook LeeDepartment of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul 03722, Korea.
Hyun Soo SeoDepartment of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul 03722, Korea.ORCID 0000-0003-0658-4724
Thao Nguyen VuDepartment of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul 03722, Korea.
Hung MaiSchool of Engineering and Applied Science, University of Pennsylvania, Philadelphia, PA 19104, USA.
An H T PhamUCI School of Biological Sciences, University of California, Irvine, CA 92617, USA.
Eris JangDepartment of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul 03722, Korea.ORCID 0000-0003-2761-9041
Young Lag ChoLegochem Biosciences, Daejeon 34302, Korea.ORCID 0000-0002-5787-9605
Karrie GoglinJ. Craig Venter Institute, La Jolla, CA 92037, USA.
Kevin NguyenJ. Craig Venter Institute, Rockville, MD 20850, USA.
Richard WhiteJ. Craig Venter Institute, Rockville, MD 20850, USA.
Roshan D'SouzaJ. Craig Venter Institute, Rockville, MD 20850, USA.
Derrick E FoutsJ. Craig Venter Institute, Rockville, MD 20850, USA.ORCID 0000-0003-4323-7668
Dongeun YongDepartment of Laboratory Medicine and Research Institute of Bacterial Resistance, Yonsei University College of Medicine, Seoul 03722, Korea.ORCID 0000-0002-1225-8477
Yonsei University · KRJ. Craig Venter Institute · USUniversity of California, Irvine · USUniversity of Pennsylvania · US

Funding

The J. Craig Venter Institute Genome Center for Infectious DiseasesU19AI110819 · NIAID · J. CRAIG VENTER INSTITUTE, INC. · PI NELSON, KAREN E., NIERMAN, WILLIAM CHARLES · 2014 to 2018
$29.7M
Ministry of Agriculture, Food and Rural Affairs 918003-4National Institute of Allergy and Infectious Diseases, National Institutes of Health, and Department of Health and Human Services U19AI110819the Ministry of Science, ICT & Future Planning (MSIP) of Korea as a Global Frontier Project H-GUARD_2014M3A6B2060509the National Institute of Health, Korea 2019ER540300R514931
6 · The paper itself

Abstract

The siderophore-antibiotic conjugate LCB10-0200 (a.k.a. GT-1) has been developed to combat multidrug-resistant Gram-negative bacteria. In this study, the in vitro activity of LCB10-0200 and LCB10-0200/avibactam (AVI) has been investigated against carbapenem-resistant

Indexed as

carbapenem resistanceLCB10-0200/AvibactamLCB10-0200 (GT-1)siderophore-antibiotic conjugate

Identifiers

PMID33923801
PMCPMC8072773
OpenAlexW3156533150

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.